Cencora, Inc. (COR) Analyst Ratings & Price Targets

Cencora, Inc.

COR · NYSE

Analyst Consensus

Buy

16 analysts

$326

Current

—

Low

$360

Average

—

High

Average target implies +10.35% versus the current price.

Analyst Ratings Synthesis

The consensus rating is Buy, backed by all 16 analysts in the supplied coverage, with a mean price target of $342. The evidence provides no low or high target, so the target spread cannot be quantified, and it does not identify the most or least bullish analyst. No analyst rating or target revisions were reported during the week. The substantive disagreement is therefore visible mainly in the earnings outlook rather than in documented target dispersion: bulls emphasize specialty-pharma demand, oncology expansion, margin gains and Cencora’s earnings beat, while bears focus on the slight revenue miss, pricing dynamics, GLP-1 effects, tariffs and funding pressure. The average target sits above the reported $306.28 close, but no target range is available.

Rating Actions

No individual rating actions have been captured for CORyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

EVERCORE ISI

JEFFERIES & CO.

JP MORGAN SECUR

MIZUHO SECURITI

MORGAN STANLEY

TD COWEN

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: COR
Type: Stock
Sector: Health Care
Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Exchange: NYSE

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #17 on the Global Fortune 500 with more than $300 billion in annual revenue. Learn more at investor.cencora.

Key Issues

Bullish view

Specialty pharmaceuticals and oncology expansion are identified as potential sources of revenue and earnings strength, while Cencora’s third-quarter earnings surprise was positive at 2.52%.

Bearish view

Pricing dynamics and GLP-1 trends may pressure revenue, and the quarter produced a 0.16% revenue miss despite the earnings beat.

Analyst Consensus

See all

Buy

16 analysts

$326

Current

—

Low

$360

Average

—

High

Average target implies +10.35% versus the current price.

Earnings History

BeatMissNo estimate

Cencora, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers